{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-012021","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.123390+00:00","generated_at":"2026-05-27T04:05:25.604418+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HCW Biologics gets FDA clearance for Phase 1 trial of HCW9302 in alopecia areata","bullets":["FDA cleared IND for HCW9302, a first-in-class IL-2 fusion protein, in moderate-to-severe alopecia areata.","Phase 1 dose-escalation trial will evaluate safety and T reg cell expansion via subcutaneous injection.","No curative FDA-approved treatments currently exist for alopecia areata.","Company plans to expand clinical development to other autoimmune diseases after Phase 1.","Founder and CEO Hing C. Wong called the clearance a milestone for the company."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-012021","json":"https://secwatch.observer/filing/0000950170-25-012021.json","markdown":"https://secwatch.observer/filing/0000950170-25-012021.md","text":"https://secwatch.observer/filing/0000950170-25-012021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025012021/0000950170-25-012021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025012021/hcwb-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:05:25.604418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}